Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4). [VICRIVIROC in trattamento combinato con un regime ART ottimale in pazienti affetti da HIV pretrattati (VICTOR E4).]

Trial Profile

Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4). [VICRIVIROC in trattamento combinato con un regime ART ottimale in pazienti affetti da HIV pretrattati (VICTOR E4).]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vicriviroc (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms VICTOR-E4
  • Sponsors Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 13 Jan 2014 Actual end date changed as reported in ClinicalTrials.gov record.
    • 15 Mar 2010 Status changed from active, no longer recruiting to completed.
    • 20 Feb 2010 Primary endpoint 'Virological response rate' has not been met; results reported at CROI 2010.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top